对杜申尼肌肉衰竭的心脏疗法
Md Nur Ahad Shah1, Toshifumi Yokota2
1Department of Medical Genetics, University of Alberta, Edmonton, AB, Canada.
Therapeutic advances in neurological disorders
|July 10, 2023
概括
杜氏肌肉发育不良 (DMD) 的治疗重点是心脏并发症,这是主要的生存决定因素. 目前的治疗方法延缓了进展,但仍然需要治疗DMD.
科学领域:
- 神经学 神经学
- 心脏病学 心脏病学
- 遗传学 是一个遗传学.
背景情况:
- 杜氏肌肉发育不良 (DMD) 导致严重的骨,呼吸道和心脏问题.
- 心肌病现在是DMD患者生存率的主要限制因素.
- 肺部护理的进步降低了呼吸道并发症的死亡率.
研究的目的:
- 审查DMD的已批准和正在研究的治疗方法.
- 专注于解决DMD心脏表现的治疗方法.
- 总结治疗方法及其局限性.
主要方法:
- 审查关于DMD治疗的当前文献.
- 对已批准的治疗方法和临床试验候选者的分析.
- 专注于针对DMD病理生理学和心脏影响的疗法.
主要成果:
- 几种治疗策略对DMD有希望,包括基因疗法和细胞疗法.
- 已批准的治疗方法和临床试验候选药物在有效性和适用性方面各不相同.
- 在DMD的遗传异质性对广泛的治疗采用提出了挑战.
结论:
- 虽然取得了显著的进展,但对DMD的确切治疗方法尚未可用.
- 新兴疗法提供了希望,特别是在治疗心脏并发症方面.
- 为了克服局限性并开发有效的DMD治疗方法,进一步的研究至关重要.
相关概念视频
Cardiomyopathy II: Dilated Cardiomyopathy
11
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
11
Cardiomyopathy V: Interprofessional Care
17
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
17
Heart Failure VI: Adjunct Therapies
16
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
16
Myocarditis III: Medical Management
9
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
9
Satellite Stem Cells and Muscular Dystrophy
2.0K
Satellite stem cells or myosatellite cells are quiescent stem cells that Alexander Mauro first identified in 1961. These cells are located between the sarcolemma, the plasma membrane of muscle fibers, and the basal lamina, the connective tissue sheath covering it. These mononucleated cells are activated in response to muscle injury, can transform into myoblasts, and may form or repair muscle fibers. Myosatellite cells can provide additional myonuclei for muscle regeneration or return to a...
2.0K
Heart Failure Drugs: Inotropic Agents
633
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
633


